HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The challenge of producing skin test antigens with minimal resources suitable for human application against a neglected tropical disease; leprosy.

Abstract
True incidence of leprosy and its impact on transmission will not be understood until a tool is available to measure pre-symptomatic infection. Diagnosis of leprosy disease is currently based on clinical symptoms, which on average take 3-10 years to manifest. The fact that incidence, as defined by new case detection, equates with prevalence, i.e., registered cases, suggests that the cycle of transmission has not been fully intercepted by implementation of multiple drug therapy. This is supported by a high incidence of childhood leprosy. Epidemiological screening for pre-symptomatic leprosy in large endemic populations is required to facilitate targeted chemoprophylactic interventions. Such a test must be sensitive, specific, simple to administer, cost-effective, and easy to interpret. The intradermal skin test method that measures cell-mediated immunity was explored as the best option. Prior knowledge on skin testing of healthy subjects and leprosy patients with whole or partially fractionated Mycobacterium leprae bacilli, such as Lepromin or the Rees' or Convit' antigens, has established an acceptable safety and potency profile of these antigens. These data, along with immunoreactivity data, laid the foundation for two new leprosy skin test antigens, MLSA-LAM (M. leprae soluble antigen devoid of mycobacterial lipoglycans, primarily lipoarabinomannan) and MLCwA (M. leprae cell wall antigens). In the absence of commercial interest, the challenge was to develop these antigens under current good manufacturing practices in an acceptable local pilot facility and submit an Investigational New Drug to the Food and Drug Administration to allow a first-in-human phase I clinical trial.
AuthorsBecky L Rivoire, Stephen TerLouw, Nathan A Groathouse, Patrick J Brennan
JournalPLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 8 Issue 5 Pg. e2791 ( 2014) ISSN: 1935-2735 [Electronic] United States
PMID24874086 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antigens, Bacterial
  • Drugs, Investigational
Topics
  • Animals
  • Antigens, Bacterial (chemistry, immunology, isolation & purification, metabolism)
  • Armadillos
  • Bacteriological Techniques (methods)
  • Drug Stability
  • Drugs, Investigational (chemistry, isolation & purification, metabolism)
  • Guinea Pigs
  • Humans
  • Leprosy (diagnosis)
  • Mycobacterium leprae (immunology)
  • Neglected Diseases (diagnosis)
  • Research Design
  • Skin Tests (methods)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: